Cellectis (CLLS) Reports Q3 Loss of $0.36/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Cellectis (CLLS) Reports Q3 Loss of $0.36/Share

Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016

November 22, 2016 5:01 PM EST

- UCART19 Phase 1 trial on-going

- Successful cGMP Manufacturing for UCART123

- Strong cash position of $295 million1 as of September 30, 2016

- Additional grant of patent with broad claims covering fundamental use of gene editing technologies

- Revenues and other income of $12 million2 in the 3rd quarter of 2016

- Adjusted loss attributable to shareholders3 of $0.6 million2 in the 3rd quarter of 2016

NEW YORK--(BUSINESS WIRE)-- Regulatory News:

Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on... More